title: Multidisciplinary treatment of patients with hepatocellular carcinoma.
abstract: Hepatocellular carcinoma is one of the most common malignancies in the world. When it is diagnosed, patients can choose from among several potentially curative treatments, such as surgical resection, transplantation, ablation therapy and transcatheter arterial chemoembolization. This review will give an overview of the present management of hepatocellular carcinoma. Liver transplantation is considered the best curative option, achieving a high rate of complete response, especially in patients with small hepatocellular carcinoma and good residual liver function. However, a shortage of donor livers restricts the availability of transplantation. In addition, only a minority of patients with hepatocellular carcinoma can be treated surgically, owing to impaired hepatic reserve, multiple intrahepatic lesions, extrahepatic lesions and the inability to obtain an optimal tumor-free margin. Therefore, for most patients, other types of interventions (transcatheter arterial chemoembolization, percutaneous ethanol injection and radiofrequency ablation) have been developed. Among them, two local ablative modalities, percutaneous ethanol injection and percutaneous radiofrequency ablation, have been accepted as the only potentially curative nonsurgical treatments for hepatocellular carcinoma. Radiofrequency ablation may become a standard nonsurgical treatment option for patients with early hepatocellular carcinoma.
authors.affiliation: Kagawa Medical University, Third Department of Internal Medicine, 1750-1 Ikenobe Miki-cho, Kita-gun, Kagawa 761-0793, Japan. tmasaki@kms.ac.jp
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masaki
authors.forename: Asahiro
authors.initials: A
authors.lastname: Morishita
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kurokohchi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kuriyama
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology / Q000628:therapy*